Ablaze Pharmaceuticals and Yonghe Pharma Initiate Development and Manufacturing Services Agreement for Targeted Radiopharmaceutical Therapies Read more
Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED Read more
Opus Genetics Announces Acquisition of the Rights to Two Gene Therapy Product Candidates for Inherited Retinal Diseases Read more
Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics Read more
Imfinzi plus Imjudo approved in Japan for advanced liver and non-small cell lung cancers, and Imfinzi approved for unresectable biliary tract and liver cancers Read more
Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases Read more
FDA approves CSL’s HEMGENIX (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B Read more
Skye Bioscience Receives FDA Authorization of Investigational New Drug Application for SBI-100 OE Read more
Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer Read more